Litcius/Paper detail

A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models

Hiroyuki Suzuki, Tomokazu Ohishi, Mika K. Kaneko, Yukinari Kato

2023Cancers11 citationsDOIOpen Access PDF

Abstract

A cancer-specific anti-PDPN mAb, LpMab-23 (mouse IgG1, kappa), was established in our previous study. We herein produced a humanized IgG1 version (humLpMab-23) and defucosylated form (humLpMab-23-f) of an anti-PDPN mAb to increase ADCC activity. humLpMab-23 recognized PDPN-overexpressed Chinese hamster ovary (CHO)-K1 (CHO/PDPN), PDPN-positive PC-10 (human lung squamous cell carcinoma), and LN319 (human glioblastoma) cells via flow cytometry. We then demonstrated that humLpMab-23-f induced ADCC and complement-dependent cytotoxicity against CHO/PDPN, PC-10, and LN319 cells in vitro and exerted high antitumor activity in mouse xenograft models, indicating that humLpMab-23-f could be useful as an antibody therapy against PDPN-positive lung squamous cell carcinomas and glioblastomas.

Topics & Concepts

PodoplaninAntibody-dependent cell-mediated cytotoxicityCancer researchMonoclonal antibodyChinese hamster ovary cellFlow cytometryAntibodyCancerLung cancerIn vitroMedicineChemistryImmunohistochemistryImmunologyPathologyInternal medicineReceptorBiochemistryGalectins and Cancer BiologyLymphatic System and DiseasesGlycosylation and Glycoproteins Research
A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models | Litcius